Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

29.53
+0.07000.24%
Post-market: 29.40-0.1300-0.44%17:48 EST
Volume:1.30M
Turnover:38.13M
Market Cap:4.69B
PE:10.64
High:29.55
Open:29.33
Low:28.69
Close:29.46
52wk High:46.48
52wk Low:25.28
Shares:158.76M
Float Shares:148.00M
Volume Ratio:1.25
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):0.1500
ROE:111.96%
ROA:7.97%
PB:7.72
PE(LYR):196.87

Loading ...

Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release

Simply Wall St.
·
Feb 20

TG Therapeutics Reports Five-Year BRIUMVI Data Showing Sustained Efficacy in Relapsing MS

Reuters
·
Feb 17

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

GlobeNewswire
·
Feb 17

TG Therapeutics Partners with Christina Applegate to Launch Multiple Sclerosis Awareness Campaign

Reuters
·
Feb 09

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

BUZZ-TG Therapeutics rises on new data for autoimmune therapy

Reuters
·
Feb 06

TG Therapeutics startet Phase-3-Studie zu Ublituximab bei Kindern und Jugendlichen mit Multipler Sklerose

Reuters
·
Feb 06

TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum

Reuters
·
Feb 06

TG Therapeutics Announces Presentation of Data for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Feb 06

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

TG Therapeutics Unveils New BRIUMVI Data in Multiple Sclerosis at ACTRIMS 2026

Reuters
·
Jan 28

TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
Jan 27

Stock Track | TG Therapeutics Soars 5.01% Intraday on High Growth Projections and Upside Potential

Stock Track
·
Jan 16

These under-the-radar stocks combine fast growth with big upside potential

Dow Jones
·
Jan 15

TG Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jan 15

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

TIPRANKS
·
Jan 15

TG Therapeutics Shares Hit Highest Since November, Last up 12.9% After Prelim 2025 Sales Top Estimate

THOMSON REUTERS
·
Jan 14

Unusually active option classes on open January 14th

TIPRANKS
·
Jan 14

Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales

Stock Track
·
Jan 14